Octagon Capital invests in public and private healthcare companies globally. The company manages capital on behalf of global institutions including university endowments, non-profit foundations, family offices, pension funds and established asset managers.

Octagon Capital

Octagon Capital invests in public and private healthcare companies globally, with a focus in the US and China. We strive to build long-term investments and partner with our portfolio companies to support innovation. Octagon manages capital on behalf of global institutions including university endowments, non-profit foundations, family offices, pension funds and established asset managers.

Vedere Bio ll

Octagon Capital Advisors

Congratulations to our portfolio company Numab Therapeutics AG on their announcement that Johnson & Johnson has entered into a definitive agreement to acquire its wholly-owned subsidiary for the global rights to a novel, investigational first-in-class bispecific antibody, NM26, in an all-cash transaction of approximately $1.25 billion.  Additional details can be found in the press release below: 
 
https://lnkd.in/erfpth76

This transaction validates Numab's platform and we are excited to continue partnering with them.  Great job by the entire Numab Therapeutics AG team!

*This post is for informational purposes only and is not intended as investment advice or an offer of solicitation with respect to the purchase of any investment. Investing with any investment firm is suitable only for qualified investors that fully understand the risks of such an investment.

Congratulations to our portfolio company Aktis Oncology on their collaboration agreement with Eli Lilly and Company to generate anticancer radiopharmaceuticals.  Additional details can be found in the press release below: 
 
https://lnkd.in/eupbNY4q

We are super excited for the Aktis team!

*This post is for informational purposes only and is not intended as investment advice or an offer of solicitation with respect to the purchase of any investment. Investing with any investment firm is suitable only for qualified investors that fully understand the risks of such an investment.

Congratulations to our portfolio company Bluejay Therapeutics on successfully raising a $182m oversubscribed Series C financing round! Additional details can be found in the press release below: 
 
https://lnkd.in/duthsvzW

In addition to the Series C investment, Octagon had previously invested in Bluejay’s Series A and Series B financings. We are inspired by Bluejay’s progress to date and look forward to continuing to be a thought partner for Keting Chu and the management team as they continue to grow their platform. 

*This post is for informational purposes only and is not intended as investment advice or an offer of solicitation with respect to the purchase of any investment. Investing with any investment firm is suitable only for qualified investors that fully understand the risks of such an investment.

We are thrilled to share that Alpine Immune Sciences, Inc. (Nasdaq: ALPN) announced that it has entered into a definitive agreement to be acquired by Vertex Pharmaceuticals (Nasdaq: VRTX) for $65.00 per share in cash, or a total of $4.9 billion. Below is a link to the press release:
 
https://lnkd.in/evPRBg7J
 
Octagon began investing in Alpine in September 2022 and grew the position to be one of our largest core holdings. We are elated that Vertex recognizes Alpine’s talented team along with their protein engineering and immunotherapy capabilities. Congratulations to both the Alpine Immune Sciences, Inc. and Vertex Pharmaceuticals teams!

*This post is for informational purposes only and is not intended as investment advice or an offer of solicitation with respect to the purchase of any investment. Investing with any investment firm is suitable only for qualified investors that fully understand the risks of such an investment.

We are pleased to announce one of our private investments, ProfoundBio entered into an agreement to be acquired by Genmab (NASDAQ: GMAB) for $1.8B USD in an all-cash deal. The acquisition is expected to close in the first half of 2024. Octagon invested in ProfoundBio’s Series B financing earlier this year and is thrilled about the outcome. 
 
As stated by Genmab’s President and CEO, Jan van de Winkel, Ph.D., “We believe that ProfoundBio’s ADC candidates, proprietary technology platforms and talented team will be a great addition to Genmab and that, together, we will be able to accelerate the development of innovative, differentiated antibody therapies for cancer patients.” Additional details can be found in the press release below: 
 
https://lnkd.in/eby29f-6

We are super excited for the entire ProfoundBio team and are eager to see Genmab’s advancement of ADCs and ADC technologies for the treatment of cancer.  Congratulations to both teams!

*This post is for informational purposes only and is not intended as investment advice or an offer of solicitation with respect to the purchase of any investment. Investing with any investment firm is suitable only for qualified investors that fully understand the risks of such an investment. Octagon Capital Advisors LP is an investment adviser registered with the United States Securities and Exchange Commission.

We are pleased to announce one of our private investments, AnHeart Therapeutics entered into an agreement to be acquired by Nuvation Bio (NYSE: NUVB) in an all-stock deal. The acquisition is expected to close in the second quarter of 2024. As a current board member and the lead investor in AnHeart’s Series B financing we worked closely with AnHeart’s management team throughout the negotiations and are very pleased about the outcome. 
 
As stated by Nuvation Bio’s Founder, President and CEO, David Hung M.D., “AnHeart’s lead asset, taletrectinib, which will become our lead asset as it completes two pivotal studies, is a differentiated, next-generation ROS1 inhibitor with a potentially best-in-class profile that may overcome the significant limitations of existing therapies. We are impressed by what the AnHeart team has done to develop this asset and intend to build on the progress made to date.” Additional details can be found in the press release below: 
 
https://lnkd.in/emxNUxGF
 
We are super excited for the entire AnHeart Therapeutics team and are eager to see Nuvation Bio’s advancement of Taletrectinib to treat patients with ROS1 NSCLC.  Congratulations to both teams! 

*This post is for informational purposes only and is not intended as investment advice or an offer of solicitation with respect to the purchase of any investment.  Investing with any investment firm is suitable only for qualified investors that fully understand the risks of such an investment. Octagon Capital Advisors LP is an investment adviser registered with the United States Securities and Exchange Commission.

We are excited to announce the latest private investment in our portfolio, ProfoundBio.
 
ProfoundBio is a US-based biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for patients with cancer. ProfoundBio recently announced that it completed an oversubscribed Series B financing which will primarily be used to accelerate the development of its comprehensive ADC portfolio, including the planned pivotal trial of rinatabart sesutecan (Rina-S) for the treatment of ovarian cancer. Below is a link to the press release:
 
https://lnkd.in/ehRqprNS
 
We are delighted to be a thought partner for ProfoundBio’s management team as they continue to develop innovative ADCs with the potential for improved clinical outcomes for patients. Congrats to the ProfoundBio team!

*This post is for informational purposes only and is not intended as investment advice or an offer of solicitation with respect to the purchase of any investment. Investing with any investment firm is suitable only for qualified investors that fully understand the risks of such an investment. Octagon Capital Advisors LP is an investment adviser registered with the United States Securities and Exchange Commission.

We are thrilled to share that CymaBay Therapeutics announced that it has agreed to be acquired by Gilead Sciences for $32.50 per share in cash, or a total of $4.3 billion. Below is a link to the press release:
 
https://lnkd.in/gZi7p-4x
 
Octagon began investing in CymaBay in December 2022 and grew the position to be one of our largest core holdings. Congratulations to the entire  team at CymaBay Therapeutics!

*This post is for informational purposes only and is not intended as investment advice or an offer of solicitation with respect to the purchase of any investment.  Investing with any investment firm is suitable only for qualified investors that fully understand the risks of such an investment. Octagon Capital Advisors LP is an investment adviser registered with the United States Securities and Exchange Commission.

We are pleased to announce one of our private investments, ArriVent Biopharma, had their IPO on January 26 and is now trading on NASDAQ under the symbol AVBP. Additional details can be found in the press release:
 
https://lnkd.in/ep_24qFs
 
ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
 
We are super excited for the entire ArriVent team and look forward to continuing to be thought partners as they continue their important work.  Congratulations ArriVent Biopharma!

*This post is for informational purposes only and is not intended as investment advice or an offer of solicitation with respect to the purchase of any investment. Investing with any investment firm is suitable only for qualified investors that fully understand the risks of such an investment. Octagon Capital Advisors LP is an investment adviser registered with the United States Securities and Exchange Commission.

We are thrilled to announce two recent licensing agreements for Allorion Therapeutics.
 
The company entered into an exclusive option and global license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and commercialize a novel epidermal growth factor receptor (EGFR) L858R mutated allosteric inhibitor, as a potential new treatment for advanced EGFR-mutant non-small cell lung cancer (NSCLC). Allorion is eligible to receive upfront and near-term payments of up to $40 million, and additional development and commercial milestone payments of over $500 million, as well as tiered royalties on net sales worldwide. Below is a link to the press release:
 
https://lnkd.in/eaKewe6y
 
The company also entered into another exclusive license agreement with Avenzo Therapeutics, Inc., a clinical-stage biotech company developing next generation oncology therapeutics, to develop and commercialize AVZO-021 (formerly ARTS-021), a potentially best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor globally (excluding Greater China). As part of the agreement, Avenzo also receives an exclusive option for an additional preclinical program planned for IND submission in early 2025. Allorion will receive an upfront payment of $40 million and be eligible to receive additional payments based on achievement of certain development, regulatory and commercial milestones and tiered royalties on net sales by Avenzo. Potential payments for both programs may total more than $1 billion. Below is a link to the press release:
 
https://lnkd.in/eFGYNAFF
 
*This post is for informational purposes only and is not intended as investment advice or an offer or solicitation with respect to the purchase of any investment. Investing with any investment firm is suitable only for qualified investors that fully understand the risks of such an investment. Octagon Capital Advisors LP is an investment adviser registered with the United States Securities and Exchange Commission.

news impact assignment basic	general
public peers	general	Sep 3, 2024 5:50 AM	3adb9347
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Sep 3, 2024 8:44 AM	d126af73
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	3d402ec3
crunchbase profile	general
li profile	general	Sep 3, 2024 5:50 AM	6a69968c
translate crunchbase fundingrounds	general
peers	general	Sep 3, 2024 5:50 AM	22979eb4
news basic	general	Sep 3, 2024 5:50 AM	a00595c8
bundesanzeiger	filings
financials download nd	financials
private financials	financials

OCTA

COM:OCTAGONINVESTMENTS

Octagon Capital